Does DUPILUMAB Cause Product use in unapproved indication? 33,452 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 33,452 reports of Product use in unapproved indication have been filed in association with DUPILUMAB (Dupixent). This represents 8.8% of all adverse event reports for DUPILUMAB.
33,452
Reports of Product use in unapproved indication with DUPILUMAB
8.8%
of all DUPILUMAB reports
317
Deaths
1,795
Hospitalizations
How Dangerous Is Product use in unapproved indication From DUPILUMAB?
Of the 33,452 reports, 317 (0.9%) resulted in death, 1,795 (5.4%) required hospitalization, and 26 (0.1%) were considered life-threatening.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DUPILUMAB. However, 33,452 reports have been filed with the FAERS database.
What Other Side Effects Does DUPILUMAB Cause?
Pruritus (44,279)
Dermatitis atopic (33,670)
Rash (30,895)
Injection site pain (27,799)
Drug ineffective (23,712)
Dry skin (20,239)
Eczema (20,020)
Product dose omission issue (18,189)
Condition aggravated (16,459)
Arthralgia (15,176)
What Other Drugs Cause Product use in unapproved indication?
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
TACROLIMUS (5,057)
CYCLOSPORINE (5,019)
Which DUPILUMAB Alternatives Have Lower Product use in unapproved indication Risk?
DUPILUMAB vs DURAGESIC
DUPILUMAB vs DUROGESIC
DUPILUMAB vs DUROTEP MT
DUPILUMAB vs DURVALUMAB
DUPILUMAB vs DUTASTERIDE